FDA Clears Quest Diagnostic's First HSV-1, 2 Detection Test - Analyst Blog

By
A A A

Shares of leading diagnostics information company Quest Diagnostics Inc. ( DGX ) rose 4.45% to close at $57.99 yesterday. This was since the company announced the U.S. Food and Drug Administration (FDA) 510(k) clearance and receipt of CLIA (Clinical Laboratory Improvement Amendments) moderate complexity categorization for its Focus Diagnostics business' new Simplexa HSV 1 & 2 Direct molecular test on the 3M Integrated Cycler.

This Simplexa test, the first molecular test to be approved by the FDA that enables qualitative detection and differentiation of herpes simplex virus 1 (HSV-1) and herpes simplex virus 2 (HSV-2) in cerebrospinal fluid (CSF) in patients suffering from central nervous system (CNS) infection, including encephalitis. This CE marked test delivered 100% and 98% sensitivity in clinical studies for detection of HSV-1 and HSV-2, respectively.

Encephalitis is an inflammation of the brain often caused by the herpes simplex or other viruses. The availability of this Simplexa HSV 1 & 2 will enable the healthcare providers to take more informed therapeutic decisions in a timely manner for patients suffering from encephalitis. We remain confident about the efficacy of this test and expect the recent FDA approval to seamlessly strengthen the company's foothold in the U.S. companion diagnostic market.

Quest Diagnostics generated revenue of $7.1 billion in FY13. The company renders services through its other businesses like AmeriPath, Dermpath Diagnostics, Focus Diagnostics and Athena Diagnostics.  Focus Diagnostics manufactures Simplexa HSV 1 & 2 Direct, which has been launched commercially in the U.S.  Focus Diagnostics is set to become the first company to deliver diagnostic resolution for the emerging infectious diseases. Its major achievements include assays for West Nile Virus, SARS and Influenza A H1N1.

Currently, Quest Diagnostics has a Zacks Rank #4 (Sell). Some better-ranked stocks in the broader healthcare industry are Chemed Corp. ( CHE ), China Cord Blood Corporation ( CO ) and PharMerica Corporation ( PMC ).  Chemed Corp. sports a Zacks Rank #1 (Strong Buy) while China Cord Blood Corporation and PharMerica Corporation carry a  Zacks Rank #2 (Buy).



CHEMED CORP (CHE): Free Stock Analysis Report

CHINA CORD BLD (CO): Free Stock Analysis Report

QUEST DIAGNOSTC (DGX): Free Stock Analysis Report

PHARMERICA CORP (PMC): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: CNS , CHE , CO , DGX , PMC

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Budgeting for Baby
Budgeting for Baby                  
A Home to Retire In
A Home to Retire In                 

Stocks

Referenced

0%
100%
100%
100%
100%

Most Active by Volume

86,692,048
  • $16.82 ▼ 1.35%
66,073,054
  • $13.30 ▼ 6.27%
54,801,491
  • $14.59 ▼ 1.35%
54,305,010
  • $76.55 ▼ 3.15%
53,982,567
  • $3.42 ▼ 2.01%
53,146,472
  • $97.21 ▼ 1.60%
50,334,521
  • $99.18 ▼ 1.56%
44,049,276
  • $25.03 ▼ 0.56%
As of 10/1/2014, 04:15 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com